Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Macitentan in pulmonary hypertension due to left ventricular dysfunction

Open access
Vachiéry, Jean-Luc, Delcroix, Marion, Al-Hiti, Hikmet, Efficace, Michela, Hutyra, Martin, Lack, Gabriela, Papadakis, Kelly, Rubin, Lewis J. · 2018 · European Respiratory Journal

Abstract

The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH. 63 patients with PH-LHD and diastolic pressure gradient ≥7 mmHg and pulmonary vascular resistance (PVR) >3WU were randomised to macitentan 10 mg (n=31) or placebo (n=32) for 12 weeks. The main end-point assessed a composite of significant fluid retention (weight gain ≥5% or ≥5 kg because of fluid overload or parenteral diuretic administration) or worsening in New York Heart Association functional class from baseline to end of treatment. Exploratory end-points included changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) and haemodynamics at week 12. Seven macitentan-treated and four placebo-treated patients experienced significant fluid retention/worsening functional class; treatment difference, 10.08% (95% CI −15.07–33.26; p=0.34). The difference, driven by the fluid retention component, was apparent within the first month. At week 12,versus placebo, the macitentan group showed no change in PVR, mean right atrial pressure or pulmonary arterial wedge pressure; a non-significant increase in cardiac index (treatment effect 0.4 (95% CI 0.1–0.7) L·min−1·m−2) and decrease in NT-proBNP (0.77 (0.55–1.08)) was observed. Adverse events and serious adverse events were numerically more frequent with macitentan versus placebo. Macitentan-treated patients were quantitatively more likely to experience significant fluid retention versus placebo. Macitentan resulted in no significant changes in any exploratory end-points.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.01886-2017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 207

Metadata

Authors
Vachiéry, J.-L., Delcroix, M., Al-Hiti, H., Efficace, M., Hutyra, M., Lack, G., Papadakis, K., & Rubin, L. J.
Venue
European Respiratory Journal
Published
2018-02
Volume
51
Issue
2
Pages
1701886
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2786647296
Cited by
207
References
2
FWCI
15.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macitentan in pulmonary hypertension due to left ventricular dysfunction. https://app.cochat.ai/papers/10.1183/13993003.01886-2017
The paper
Vachiéry, J.-L., Delcroix, M., Al-Hiti, H., Efficace, M., Hutyra, M., Lack, G., Papadakis, K., & Rubin, L. J. (2018). Macitentan in pulmonary hypertension due to left ventricular dysfunction. European Respiratory Journal. https://doi.org/10.1183/13993003.01886-2017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.